Smith & Nephew SNATS Net Income 2006-2018 | SNN

Smith & Nephew SNATS annual/quarterly net income history and growth rate from 2006 to 2018. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
  • Smith & Nephew SNATS net income for the quarter ending June 30, 2018 was $0.000B, a NAN% increase year-over-year.
  • Smith & Nephew SNATS net income for the twelve months ending June 30, 2018 was $0M, a 100% decline year-over-year.
  • Smith & Nephew SNATS annual net income for 2017 was $0.767B, a 2.17% decline from 2016.
  • Smith & Nephew SNATS annual net income for 2016 was $0.784B, a 91.22% increase from 2015.
  • Smith & Nephew SNATS annual net income for 2015 was $0.41B, a 18.16% decline from 2014.
Smith & Nephew SNATS Annual Net Income
(Millions of US $)
2017 $767
2016 $784
2015 $410
2014 $501
2013 $556
2012 $729
2011 $582
2010 $615
2009 $472
2008 $377
2007 $316
2006 $745
2005 $341
Smith & Nephew SNATS Quarterly Net Income
(Millions of US $)
Q2 2018 $0
Q4 2017 $0
Q2 2017 $0
Q4 2016 $0
Q4 2015 $0
Q2 2015 $0
Q4 2014 $160
Q3 2014 $102
Q2 2014 $89
Q1 2014 $150
Q4 2013 $162
Q3 2013 $122
Q2 2013 $129
Q1 2013 $143
Q4 2012 $142
Q3 2012 $134
Q2 2012 $292
Q1 2012 $161
Q4 2011 $140
Q3 2011 $133
Q2 2011 $153
Q1 2011 $156
Q4 2010 $182
Q3 2010 $137
Q2 2010 $137
Q1 2010 $159
Q4 2009 $128
Q3 2009 $128
Q2 2009 $118
Q1 2009 $98
Q4 2008 $115
Q3 2008 $74
Q2 2008 $103
Q1 2008 $83
Q4 2007 $101
Q3 2007 $13
Q2 2007 $111
Q1 2007 $91
Q4 2006 $140
Q3 2006 $93
Q2 2006 $100
Q1 2006 $419
Q4 2005 $88
Q3 2005 $62
Q2 2005 $98
Q1 2005 $93
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $16.204B $4.765B
Smith & Nephew is a global medical device company. The company markets clinically superior products, principally in orthopaedics, endoscopy and wound management to deliver cost-effective solutions, significant physicianadvantage and real patient benefits. A continuous process of supplying new and innovative products is supported by substantial R&D investment todeliver new levels of healing to patients throughout the world
Stock Name Country Market Cap PE Ratio
Medtronic (MDT) Ireland $123.359B 18.44
Abbott Laboratories (ABT) United States $122.504B 24.82
Stryker (SYK) United States $59.911B 22.58
Boston Scientific (BSX) United States $47.118B 23.81
Baxter (BAX) United States $34.158B 22.06
Zimmer Biomet Holdings (ZBH) United States $21.876B 14.19
ResMed (RMD) United States $15.783B 30.10
Perrigo (PRGO) Ireland $7.660B 11.63
Bio-Rad Laboratories (BIO) United States $7.281B 46.56
Canopy Growth (CGC) Canada $6.819B 0.00
Hill-Rom Holdings (HRC) United States $6.051B 18.93
Aurora Cannabis (ACB) Canada $5.521B 29.16
Haemonetics (HAE) United States $5.243B 46.11
Insulet (PODD) United States $4.521B 0.00
ICU Medical (ICUI) United States $4.481B 24.97
Hutchison China MediTech (HCM) China $4.254B 0.00
GW Pharmaceuticals (GWPH) United Kingdom $3.594B 0.00
Neogen (NEOG) United States $3.108B 47.06
Agios Pharmaceuticals (AGIO) United States $2.958B 0.00
NuVasive (NUVA) United States $2.733B 25.43
National Vision Holdings (EYE) United States $2.256B 43.63
Quidel (QDEL) United States $1.932B 25.18
NxStage Medical (NXTM) United States $1.877B 0.00
Aphria (APHA) $1.356B 0.00
Phibro Animal Health (PAHC) United States $1.315B 18.61
AtriCure (ATRC) United States $1.130B 0.00
Cardiovascular Systems (CSII) United States $0.974B 1402.00
VAREX IMAGING (VREX) United States $0.891B 17.84
PetIQ (PETQ) United States $0.812B 21.04
Cerus (CERS) United States $0.741B 0.00
Meridian Bioscience (VIVO) United States $0.736B 23.45
Surmodics (SRDX) United States $0.721B 109.84
OraSure Technologies (OSUR) United States $0.705B 39.69
Eagle Pharmaceuticals (EGRX) United States $0.660B 21.18
Omeros (OMER) United States $0.643B 0.00
Lantheus Holdings (LNTH) United States $0.626B 19.38
MacroGenics (MGNX) United States $0.566B 0.00
LeMaitre Vascular (LMAT) United States $0.476B 23.36
NanoString Technologies (NSTG) United States $0.470B 0.00
Owens & Minor (OMI) United States $0.411B 4.65
Quanterix (QTRX) United States $0.409B 0.00
TG Therapeutics (TGTX) United States $0.369B 0.00
Insys Therapeutics (INSY) United States $0.356B 0.00
Evolus (EOLS) United States $0.336B 0.00
Utah Medical Products (UTMD) United States $0.304B 19.69
VAPOTHERM INC (VAPO) United States $0.294B 0.00
Cytosorbents (CTSO) United States $0.282B 0.00
Surface Oncology (SURF) United States $0.216B 0.00
Neptune Technologies & Bioresources Inc (NEPT) Canada $0.213B 0.00
Bovie Medical (BVX) United States $0.198B 0.00
BioLife Solutions (BLFS) United States $0.196B 265.00
Rockwell Medical (RMTI) United States $0.163B 0.00
Chimerix (CMRX) United States $0.152B 0.00
Fonar (FONR) United States $0.133B 6.69
Imprimis Pharmaceuticals (IMMY) United States $0.125B 0.00
Chembio Diagnostics (CEMI) United States $0.101B 0.00
Female Health (VERU) United States $0.088B 0.00
United-Guardian (UG) United States $0.076B 15.96
Oramed Pharmaceuticals (ORMP) United States $0.067B 0.00
InfuSystems Holdings (INFU) United States $0.067B 0.00
Trinity Biotech (TRIB) Ireland $0.062B 17.07
CAS Medical Systems (CASM) United States $0.044B 0.00
Conatus Pharmaceuticals (CNAT) United States $0.042B 0.00
ImmuCell (ICCC) United States $0.040B 0.00
Neurotrope (NTRP) United States $0.031B 0.00
Myomo (MYO) United States $0.021B 0.00
InVivo Therapeutics Holdings (NVIV) United States $0.016B 0.00
Capricor Therapeutics (CAPR) United States $0.016B 0.00
Senestech (SNES) United States $0.014B 0.00
Akers Biosciences Inc (AKER) United States $0.012B 0.00
Cellectar Biosciences (CLRB) United States $0.010B 0.00
Valeritas Holdings (VLRX) United States $0.009B 0.00
NeuroMetrix (NURO) United States $0.006B 0.00